UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death

Nature chemical biology, 2013-09, Vol.9 (9), p.548-556

2013

Volltextzugriff (PDF)

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury

Molecular cancer therapeutics, 2018-03, Vol.17 (3), p.603-613

2018

Volltextzugriff (PDF)

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers

Experimental cell research, 2015-03, Vol.332 (2), p.267-277

2015

Volltextzugriff (PDF)

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1

Scientific reports, 2017-08, Vol.7 (1), p.9226-14, Article 9226

2017

Volltextzugriff (PDF)

Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma

Clinical cancer research, 2007-10, Vol.13 (19), p.5942-5951

2007

Volltextzugriff (PDF)

Cdc7 Kinase Inhibitors: 5-Heteroaryl-3-Carboxamido-2-Aryl Pyrroles as Potential Antitumor Agents. 1. Lead Finding

Journal of medicinal chemistry, 2010-10, Vol.53 (20), p.7296-7315

2010

Volltextzugriff (PDF)

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)

Bioorganic & medicinal chemistry letters, 2009-06, Vol.19 (11), p.2924-2927

2009

Volltextzugriff (PDF)

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Molecular cancer therapeutics, 2016-04, Vol.15 (4), p.628-639

2016

Volltextzugriff (PDF)

High-content analysis of kinase activity in cells

Combinatorial chemistry & high throughput screening, 2008-08, Vol.11 (7), p.523-536

2008

Volltextzugriff (PDF)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2016-01, Vol.108 (1), p.1

2016

Volltextzugriff (PDF)

Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4185-TPS4185

2023

Volltextzugriff (PDF)

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

British journal of cancer, 2015-12, Vol.113 (12), p.1730-1734

2015

Volltextzugriff (PDF)

Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24), p.10255-10264

2010

Volltextzugriff (PDF)

Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan™ assays

European journal of cell biology, 2009-12, Vol.88 (12), p.779-785

2009

Volltextzugriff (PDF)

Abstract 4843: NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4843-4843

2018

Volltextzugriff (PDF)

Stereoselective synthesis of 3,4‐dihydropyrrolo[1,2‐a]pyrazin‐1(2H)‐one derivatives as PIM kinase inhibitors inspired from marine alkaloids

Chirality (New York, N.Y.), 2022-11, Vol.34 (11), p.1437-1452

2022

Volltextzugriff (PDF)

Stereoselective synthesis of 3,4‐dihydropyrrolopyrazin‐1(2H)‐one derivatives as PIM kinase inhibitors inspired from marine alkaloids

Chirality (New York, N.Y.), 2022-11, Vol.34 (11), p.1437-1452

2022

Volltextzugriff (PDF)

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.1006-1016

2012

Volltextzugriff (PDF)

Alkylsulfanyl-1,2,4-triazoles, a New Class of Allosteric Valosine Containing Protein Inhibitors. Synthesis and Structure–Activity Relationships

Journal of medicinal chemistry, 2013-01, Vol.56 (2), p.437-450

2013

Volltextzugriff (PDF)

Identification of unprecedented ATP-competitive choline kinase inhibitors

Bioorganic & medicinal chemistry letters, 2021-11, Vol.51, p.128310-128310, Article 128310

2021

Volltextzugriff (PDF)

Abstract 1324: NMS-P088, a novel FLT3, KIT and CSF1R inhibitor, is a promising clinical candidate for AML and CMML treatment

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1324-1324

2019

Volltextzugriff (PDF)

Multiparametric cell cycle analysis by automated microscopy

Journal of biomolecular screening, 2006-09, Vol.11 (6), p.586-598

2006

Volltextzugriff (PDF)

1 – 25 von 152

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(126)

Publikationsform

Artikel
(151)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Life Sciences & Biomedicine
(42)
Humans
(38)
Cell Line, Tumor
(20)
Pharmacology & Pharmacy
(20)
Animals
(19)
Antineoplastic Agents - Pharmacology
(19)
Chemistry, Medicinal
(16)
Oncology
(16)
Mice
(15)
Chemistry
(12)
Physical Sciences
(12)
Cell Proliferation - Drug Effects
(11)
Structure-Activity Relationship
(11)
Antineoplastic Agents - Chemistry
(10)
Protein Kinase Inhibitors - Pharmacology
(10)
Biochemistry & Molecular Biology
(9)
Chemistry, Organic
(9)
Mice, Nude
(9)
Female
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Discovery of Entrectinib: A New 3‑Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c‑ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury

Discovery of 2‑[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro‑1H‑isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP‑1 Inhibitor for Cancer Therapy

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1

Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma

Cdc7 Kinase Inhibitors: 5-Heteroaryl-3-Carboxamido-2-Aryl Pyrroles as Potential Antitumor Agents. 1. Lead Finding

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

High-content analysis of kinase activity in cells

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan™ assays

Abstract 4843: NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma

Stereoselective synthesis of 3,4‐dihydropyrrolo[1,2‐a]pyrazin‐1(2H)‐one derivatives as PIM kinase inhibitors inspired from marine alkaloids

Stereoselective synthesis of 3,4‐dihydropyrrolopyrazin‐1(2H)‐one derivatives as PIM kinase inhibitors inspired from marine alkaloids

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies

Alkylsulfanyl-1,2,4-triazoles, a New Class of Allosteric Valosine Containing Protein Inhibitors. Synthesis and Structure–Activity Relationships

Identification of unprecedented ATP-competitive choline kinase inhibitors

Abstract 1324: NMS-P088, a novel FLT3, KIT and CSF1R inhibitor, is a promising clinical candidate for AML and CMML treatment

Multiparametric cell cycle analysis by automated microscopy

Suchergebnisse filtern